Orexigen Therapeutics (NASDAQ:OREX) consumer-focused re-launch of Contrave continues to be successful with a 39% increase in prescriptions in the United States in Q117 compared to Q416. Outside of the US, progress continues as the product has launched in 14 countries, with another seven expected by the end of the year, including the Nordic countries, where Orexigen has just signed a local commercial and distribution partner.
Successful patient-centric campaign
A shift from previous partner Takeda's (T:4502) healthcare provider-focused marketing to a campaign focused on consumers (but with continued detailing of high prescribing physicians) has yielded a dramatic increase in prescriptions. Prescriptions increased 39% in Q117 versus Q416 and they now have approximately 50% of the branded obesity market (~8% of the total) according to Symphony Health.
To read the entire report Please click on the pdf File Below